ReviewActa diabetologica2026
Therapeutic strategies to enhance proliferation in diabetic wound contraction: a comprehensive review from 1991-2025.
Review in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global rise in diabetes mellitus has been accompanied by a marked increase in associated complications, most notably impaired wound healing. Diabetic non-healing wounds arise from multifactorial pathophysiological mechanisms, including excessive and prolonged inflammation, immune dysregulation, impaired angiogenesis, defective fibroblast-to-myofibroblast transition and aberrant growth factor signaling. These abnormalities delay wound contraction and re-epithelialization, increasing susceptibility to infection, chronic ulceration and limb amputation. Traditional and complementary approaches such as herbal formulations, Ayurvedic practices, and natural bioactive compounds have demonstrated potential in mitigating oxidative stress, modulating inflammation and promoting neovascularization. In parallel, advanced technological interventions, including nanocomposite hydrogels, smart and responsive biomaterials, gene therapy and targeted growth factor delivery systems, are being developed to create a pro-regenerative wound microenvironment. Modern clinical strategies such as electromagnetic therapy, negative pressure wound therapy, electrospun nanofiber scaffolds and 3D/4D bioprinting further contribute to enhanced wound contraction and tissue regeneration. Additionally, bioengineered skin substitutes, stem cell-based therapies and innovative growth factor delivery platforms offer promising translational prospects. This review critically summarizes traditional, complementary, and innovative approaches reported up to 2025, with an emphasis on smart biomaterials, emerging therapies and relevant preclinical models, highlighting future directions for improving diabetic wound care and patient quality of life.
Indexed as
Identifiers
42334597What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.